Skip main navigation
Close Drawer MenuOpen Drawer Menu
APA Publishing Logo

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Site maintenance Monday, July 8th, 2024. Please note that access to some content and account information will be unavailable on this date.
Back to table of contents
PsychopharmacologyFull Access

Industry Briefs

Published Online:2 Oct 2015

Label Changes for Geodon, Daytrana, and Tegretol

Recently, the Food and Drug Administration (FDA) announced labeling changes for the following products:

  • Daytrana (methylphenidate transdermal system): warning for risk of persistent loss of skin pigmentation at and around the application site

  • Geodon (ziprasidone) Oral Suspension, Injection, and Capsule: warning for risk of severe cutaneous adverse reactions, such as Stevens-Johnson syndrome

  • Tegretol (carbamazepine): warning for risk of hyponatremia and a contraindication for patients with rare hereditary problems of fructose intolerance

Back to Psychopharmacology Newsletter Table of Contents